XML 360 R107.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Equity (Share-based Payments to Employees, Restricted Shares) (Details) - Restricted shares [Member] shares in Thousands, $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2021 USD ($) shares
Officers and senior employees [Member] | June 30, 2016 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 990 |
Fair value at the grant date (Million) | $ | $ 4.1 |
Officers and senior employees [Member] | June 20, 2017 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 2,211 |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
Fair value at the grant date (Million) | $ | $ 10.0 |
Officers and senior employees [Member] | March 6, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 1,726 |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
Fair value at the grant date (Million) | $ | $ 8.0 |
Former CEO [Member] | February 14, 2017 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
ICLs Directors (excluding ICLs CEO and Chairman of the BOD) [Member] | January 10, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 137 |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
Fair value at the grant date (Million) | $ | $ 0.6 |
ICLs Directors (excluding ICLs CEO and Chairman of the BOD) [Member] | August 20, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
ICLs Directors (excluding ICLs Chairman of the BOD) [Member] | January 3, 2017 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | [1]
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
ICLs Directors (excluding directors who are officers or directors of Israel Corporation Ltd.) [Member] | April 23, 2020 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 177 |
Vesting conditions | 3 equal tranches: (1) one third on January 1, 2021 (2) one third on January 1, 2022 (3) one third on January 1,2023 | [1]
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the Grant Date (the approval date of the annual General Meeting of shareholders). |
Fair value at the grant date (Million) | $ | $ 0.6 |
Former Chairman B O D [Member] | September 5, 2016 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 55 |
Fair value at the grant date (Million) | $ | $ 4.1 |
Former Chairman B O D [Member] | August 2, 2017 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 53 |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
Fair value at the grant date (Million) | $ | $ 0.3 |
Former Chairman B O D [Member] | August 20, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 47 |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
Fair value at the grant date (Million) | $ | $ 0.2 |
CEO [Member] | May 14, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number of instruments (thousands) | shares | 121 |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Additional information | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting where required). |
Fair value at the grant date (Million) | $ | $ 0.6 |
[1] | Vesting of the Restricted Shares would be fully accelerated if the holder ceases to serve as a director of the Company, unless he/she ceased to hold office due to those certain circumstances regarding early termination of office or imposition of enforcement measures, as set forth in Sections 231-232a and 233(2) of the Israeli Companies Law.

X
- References No definition available. + Details
Name: | icl_NumberOfInstruments
Namespace Prefix: | icl_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the method of settlement (for example, whether in cash or equity) for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 45 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 45 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 45 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 47 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=icl_RestrictedSharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_OfficersAndSeniorEmployeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_June302016Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_June202017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_March62018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_FormerCEOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_February142017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_ICLDirectorsExcludingCEOAndChairmanBODMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_January102018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_August202018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_ICLDirectorsExcludingChairmanBODMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_January32017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_ICLDirectorsEexcludingDirectorsWhoAreOfficersOrDirectorsOfILCorpLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_April232020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_FormerChairmanBODMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_September52016Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_August22017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_CEOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_May142018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |